The impact of mild induced hypothermia on the rate of transfusion and the mortality in severely injured patients: a retrospective multi-centre study

被引:7
作者
Jensen, Kai Oliver [1 ]
Held, Leonhard [4 ]
Kraus, Andrea [4 ]
Hildebrand, Frank [2 ]
Mommsen, Philipp [3 ]
Mica, Ladislav [1 ]
Wanner, Guido A. [1 ]
Steiger, Peter [5 ]
Moos, Rudolf M. [6 ]
Simmen, Hans-Peter [1 ]
Sprengel, Kai [1 ]
机构
[1] Univ Zurich, Univ Zurich Hosp, Div Trauma Surg, Raemistr 100, CH-8091 Zurich, Switzerland
[2] Univ Aachen, Dept Orthoped Trauma, Aachen, Germany
[3] Hannover Med Sch, Trauma Dept, Hannover, Germany
[4] Univ Zurich, Inst Epidemiol Biostat & Prevent, Dept Biostat, Zurich, Switzerland
[5] Univ Zurich, Div Surg Intens Care Med, Univ Zurich Hosp, Zurich, Switzerland
[6] Univ Zurich, Univ Zurich Hosp, Zurich, Switzerland
关键词
Severely injured; Induced hypothermia; Transfusion rate; Mortality; UNCONTROLLED HEMORRHAGIC-SHOCK; THERAPEUTIC HYPOTHERMIA; TRAUMA; SURVIVAL;
D O I
10.1186/s40001-016-0233-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Although under discussion, induced hypothermia (IH) is an established therapy for patients with cardiac arrest or traumatic brain injuries. The influences on coagulopathy and bleeding tendency in severely injured patients (SIP) with concomitant traumatic brain injury are most widely unclear. Therefore, the aim of this study was to quantify the effect of mild IH in SIP with concomitant severe traumatic brain injuries on transfusion rate and mortality. Methods: In this retrospective multi-centre study, SIP from three European level-1 trauma centres with an ISS >= 16 between 2009 and 2011 were included. At hospital A, patients qualified for IH with age <= 70 years and a severe head injury with an abbreviated injury scale (AIS(Head)) of >= 3. IH was defined as target core body temperature of 35 degrees C. Hypothermic patients were matched with two patients, one from hospital B and one from hospital C using age and AIS(Head). The effect of IH on the transfusion rate, complications and mortality was quantified with 95 % confidence intervals (CI). Patients not treated with IH in hospital A and those from hospital B and C, who were not matched, were used to adjust the CI for the effect of inter-hospital therapy protocol differences. Results: Mean age of patients in the IH-group (n = 43) was 35.7 years, mean ISS 30 points and sex distribution showed 83.7 % male. Mean age of matched patients in the normotherm-group (n = 86) was 36.7 years, mean ISS 33 points and there were 75.6 % males. For the hypothermic patients, we pointed out an estimate of mean difference for the number of transfused units of packed red blood cells as well as for mortality which does not indicate a decrease in the benefit gained by hypothermia. It is suggested that hypothermic patients tend to a higher rate of lung failure and thromboembolisms. Conclusion: Though tending to an increased rate of complications, there is no evidence for a difference in both; rate of transfusion and mortality in SIP. Mild IH as an option for severe head injuries seems as well-being practicable in the presence of multiple severe injuries. Further, clinical studies regarding the side effects are necessary.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 37 条
  • [31] Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study
    Mirjam Kohls
    Heinz Freisling
    Hadrien Charvat
    Isabelle Soerjomataram
    Vivian Viallon
    Veronica Davila-Batista
    Rudolf Kaaks
    Renée Turzanski-Fortner
    Krasimira Aleksandrova
    Matthias B. Schulze
    Christina C. Dahm
    Helene Tilma Vistisen
    Agnetha Linn Rostgaard-Hansen
    Anne Tjønneland
    Catalina Bonet
    Maria-Jose Sánchez
    Sandra Colorado-Yohar
    Giovanna Masala
    Domenico Palli
    Vittorio Krogh
    Fulvio Ricceri
    Olov Rolandsson
    Sai San Moon Lu
    Konstantinos K. Tsilidis
    Elisabete Weiderpass
    Marc J. Gunter
    Pietro Ferrari
    Ursula Berger
    Melina Arnold
    BMC Cancer, 22
  • [32] Participation in adjuvant clinical breast cancer trials: Does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9433 patients
    Schwentner, L.
    Van Ewijk, R.
    Kurzeder, C.
    Hoffmann, I.
    Koenig, J.
    Kreienberg, R.
    Blettner, M.
    Woeckel, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (03) : 553 - 563
  • [33] High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study
    Ling, Stephanie F.
    Broad, Eleanor
    Murphy, Rebecca
    Pappachan, Joseph M.
    Pardesi-Newton, Satveer
    Kong, Marie-France
    Jude, Edward B.
    NUTRIENTS, 2020, 12 (12) : 1 - 16
  • [34] Mortality Rate and Predictors among Patients with COVID-19 Related Acute Respiratory Failure Requiring Mechanical Ventilation: A Retrospective Single Centre Study
    de Terwangne, Christophe
    Sorgente, Antonio
    Tortora, Redente
    Cheung, Diana
    Duprez, Frederic
    Place, Sammy
    Lechien, Jerome R.
    Capulzini, Lucio
    De Cubber, Michael
    Saussez, Sven
    Taccone, Fabio Silvio
    Mashayekhi, Shahram
    JOURNAL OF CRITICAL CARE MEDICINE, 2021, 7 (01) : 21 - 27
  • [35] Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy
    Schwentner, L.
    Woeckel, A.
    Koenig, J.
    Janni, W.
    Blettner, M.
    Kreienberg, R.
    Van Ewijk, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) : 2905 - 2915
  • [36] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2014, 15 (01)
  • [37] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2014, 15